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AbstrACt
Introduction Current guidelines advise the prompt 
diagnosis and treatment of urinary tract infection (UTI) in 
children to improve both short and longer term outcomes. 
However, the risk of long-term complications following 
childhood UTI is unclear. UTI is relatively common but 
difficult to diagnose in children as symptoms are non-
specific. Diagnosis requires a urine sample, but sampling 
is difficult and infrequent, and it is not clear if sampling 
should be given greater priority in primary care. The LUCI 
study will assess the short, medium and longer term 
outcomes of childhood UTI associated with routine and 
systematic sampling practices.
Methods and analysis Two data sets will be 
established. The first will consist of routinely collected 
data (hospital, general practice (GP), microbiology) 
from children born and resident in Wales, linked via 
the Secure Anonymised Information Linkage (SAIL) 
Databank (an ‘e-cohort’). Urine sampling in this data set 
reflects normal practice ‘routine sampling’. Outcomes 
(including renal scarring, hypertension, end-stage 
renal failure, hospital admissions, GP consultations, 
antibiotic prescriptions) for children with at least one 
UTI confirmed with microbiological culture (mcUTI) or 
no mcUTI before the age of 5 will be compared. The 
second will combine data from two prospective 
observational studies (‘DUTY’ and ‘EURICA’) employing 
systematic urine sampling for children presenting 
to primary care with acute, undifferentiated illness, 
linked to routine data via SAIL (Wales) and NHS Digital 
(England). Outcomes (as above, plus features of mcUTI) 
for children with an mcUTI in this data set, identified 
through systematic urine sampling, will be compared 
with those with an mcUTI identified through routine 
urine sampling (data set 1).
Ethics and dissemination The study protocol has been 
approved by NHS Wales Research Ethics Committee and 
the Health Research Authority’s Confidentiality Advisory 
Group. Methods of innovative study design and findings 
will be disseminated through peer-review journals and 
conferences. Results will be of interest to clinical and 
policy stakeholders in the UK.
IntroduCtIon   
Urinary tract infections (UTI) are a common 
cause of acute illness in children and an 
important contributor to hospital admis-
sions for serious bacterial infection.1–7 In UK 
primary care, UTI is the cause of approxi-
mately 6% of acute illness consultations in 
children less than 5 years old.5 7 
Childhood UTI can lead to renal scar-
ring.6 8 9 Renal scarring has been linked 
with long-term complications including 
hypertension, pre-eclampsia and renal 
failure.10–12 Clinical guidelines promote the 
prompt diagnosis and treatment of UTI as 
a measure to prevent renal scarring and 
longer term complications.6 It is not clear 
what the risks of longer term complications 
are for children with UTI. A systematic 
review in 2010 found that the prevalence of 
strengths and limitations of this study
 ► Use of routinely collected data in the study allows 
the identification of rare chronic outcomes, from 
large numbers of children at risk.
 ► This multisourced data  set will allow a compari-
son of outcomes over 5 years for children with and 
without microbiologically confirmed urinary tract 
infection according to routine clinical practice; and 
compare outcomes in these groups with those ob-
served in high-quality research data using system-
atic urine sampling.
 ► This study will help prioritise interventions to im-
prove early diagnosis, sampling and treatment, po-
tentially improving health outcomes and reducing 
National Health Service costs.
 ► Using routinely collected data relies on the quality of 
coding and availability of data.
 ► Using routinely collected data limits the information 
available on the children and their outcomes.
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renal scarring following first childhood UTI was 15%.8 
Most included studies were conducted in secondary 
care and most required fever for inclusion in the study.8 
These are likely to represent more serious UTIs than 
those presenting in primary care, and this rate of renal 
scarring may not apply to all children presenting with 
UTI. The risk of long-term complications (such as hyper-
tension and renal failure) as a result of renal scarring 
following childhood UTI is also not clear, with some 
researchers questioning this association.6 13 14 A review, 
commissioned by the National Institute for Health and 
Care Excellence (NICE), concluded that ‘there are no 
appropriate studies that accurately estimate the risks of 
long term complications as a result of childhood UTI.’6
A urine sample is necessary to confirm the presence 
of UTI in childhood as the presenting symptoms are 
non-specific and similar to those found in many common 
childhood illnesses (eg, respiratory infections, gastro-
enteritis, tonsillitis, ear infections) such as high tempera-
ture, poor feeding, vomiting, lethargy and irritability.6 
Furthermore, microbiological confirmation is important 
as some children with UTI require invasive investiga-
tions.6 Children who become seriously ill and who are 
assessed in emergency departments or admitted to 
hospital will usually have their urine sampled.1 However, 
in primary care, where most acute illness is seen, urine is 
infrequently sampled. It is estimated that urine is sampled 
in fewer than 2% of acute illness consultations with chil-
dren under 5 years old in the UK.4 Studies have suggested 
that many cases of childhood UTI are missed in primary 
care.15–17 Routine practice (urine sampling based on 
clinician suspicion) is likely to miss more than two-thirds 
of UTIs in primary care.5 7 The clinical implications of 
missed childhood UTIs are not known. Increasing urine 
sampling in primary care is likely to increase the diagnosis 
of childhood microbiologically confirmed UTI (mcUTI), 
and is advocated by current guidelines, but it is not clear 
whether this is an appropriate strategy, whether outcomes 
for children would improve or to what extent it should be 
increased.4–6 15 18
Clarification is needed on two issues: First, to determine 
what the longer term outcomes are following childhood 
UTI (including those identified in primary care), and 
second, to determine whether outcomes vary according 
to sampling practice.
In this study we will describe clinical outcomes for all 
children with one or more mcUTIs aged less than 5 years 
old, compared with those with no mcUTI, using National 
Health Service (NHS) laboratory data from across Wales. 
We will examine the risk factors for being diagnosed with 
renal scarring following mcUTI.
We will also describe longer term follow-up of clin-
ical outcomes for at least 5 years following participation 
in two UK prospective cohort studies of acutely ill chil-
dren with systematic urine sampling in primary care, the 
Diagnosis of Urinary Tract infection in Young children 
(DUTY) and EURICA (a Welsh cohort study of urinary 
tract infection in children) studies.5 7 We will compare the 
outcomes of those with mcUTI identified through these 
studies (systematic urine sampling) with those identified 
through routine practice.
MEthods And dEsIgn
research objectives
The Long-term outcomes of UTI in Childhood (LUCI) 
study will use data linkage of routinely collected data sets 
and data from two cohorts of participants to answer two 
main research questions:
Research question 1: Through routine sampling, do 
children who have experienced a mcUTI aged <5 years old 
have worse outcomes (medium (0–5 years); longer term 
(>5 years)) compared with children who have not experi-
enced an mcUTI?
Research question 2: Are short-term (<12 months) and 
medium-term (1–4 years) outcomes different for chil-
dren with childhood mcUTI identified through system-
atic sampling compared with routine sampling (standard, 
clinician-led sampling)?
study design
This is a data linkage study comprising two overarching 
data sets of children. Data set 1 will comprise routinely 
collected health data from children born and resident 
in Wales. Children in this data set will have had urine 
sampled according to routine practice. Routine data 
will be available on all children for 7 years, and longer 
for some (ie, children will be followed up until the date 
of data abstraction). Data set 1 will be used to answer 
research question 1.
Data set 2 will be children who participated in the 
EURICA or DUTY studies. Children in this data set had 
their urine systematically sampled (all children presenting 
with an acute illness were asked to provide a urine 
sample). DUTY and EURICA children will be followed up 
by linking records to routinely collected health data from 
England (using NHS Digital) and Wales (using Secure 
Anonymised Information Linkage, SAIL). Follow-up will 
be for a minimum of 5 years, and longer where data are 
available. Data set 2 will be used to describe longer term 
follow-up for DUTY and EURICA study children. Those 
with mcUTI in data set 2 will be compared with those with 
mcUTI identified in data set 1 to answer research ques-
tion 2.
The study formally started in October 2016 and will 
report to funder in June 2019. A summary of the data 
sources is provided in table 1.
data providers and data sets
The EURICA and DUTY studies
This work builds on two large cohort studies of acutely 
ill children, aged less than 5 years old, presenting in 
primary care, in which mcUTI status was determined 
using systematic urine sampling.5 7 In both studies, clin-
ical and demographic data were collected and urine 
samples requested from all children included in the 
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study and analysed in NHS microbiology laboratories. 
In the EURICA study, 1003 children were recruited 
from general practitioner's (GP) practices in Wales 
between March 2008 and July 2010. 5.9 per cent of chil-
dren had mcUTI. Participants had a GP notes review 
at 6 months. In the DUTY study, 7163 children were 
recruited from GP practices in England and Wales 
between April 2010 and April 2012 and 5.6% children 
had mcUTI confirmed in NHS labs. An algorithm to 
predict UTI based on presenting symptoms and signs 
was developed. Neither study had sufficient follow-up 
to determine whether renal investigations to look for 
renal scarring had been undertaken or found. EURICA 
was funded by the National Institute for Social Care 
Table 1 Sources of data
Data provider Data source Dates available Indicative/key data items
Data set
Data set 
1 (routine 
sampling)
Data set 2 
(systematic 
sampling)
SAIL (Wales) GP January 1994 to 
October 2016
Secondary outcomes 
including antibiotic 
prescriptions, GP 
consultations, chronic 
kidney disease, 
hypertension
✓ ✓
Patient Episode Database for 
Wales (PEDW)
January 1994 to 
April 2017
Primary and secondary 
outcomes and covariates 
including renal scarring, 
hospital admission, end-
stage renal failure, VUR, 
renal/bladder surgery
✓ ✓
Welsh Demographic Service 
(WDS)
January 1994 to 
April 2017
Demographics ✓ ✓
Welsh Electronic Cohort of 
Children (WECC)
January 1994 
to September 
2011
Defines a child as ‘born in 
Wales’
✓ ✓
Datastore (data repository 
storing microbiology culture 
data from the Laboratory 
Information Management 
Systems in Wales)
2005–2014 Defines a microbiologically 
confirmed UTI
✓ ✓
Outpatient data January 1994 
to April 2017
Primary outcome—renal 
scarring
✓ ✓
Individual Health 
Boards
Radiology data January 1994 to 
January 2017
Validation of the primary 
outcome (renal scarring)
✓
NHS Digital 
(England)
Admitted patient care April 2008 to 
March 2017
Primary and secondary 
outcomes and covariates 
including renal scarring, 
hospital admission, end-
stage renal failure, VUR, 
renal/bladder surgery
✓
Outpatient April 2008 to 
March 2017
Primary outcome—renal 
scarring
✓
Bristol University 
(England and 
Wales)
DUTY April 2010 to April 
2012
Baseline characteristics, 
UTI status, presenting 
symptoms and signs, initial 
clinical management
✓
Cardiff University 
(Wales)
EURICA July 2008 to July 
2010
Baseline characteristics, 
UTI status, presenting 
symptoms and signs, initial 
clinical management
✓
DUTY, Diagnosis of Urinary Tract infection in Young children; EURICA, Welsh cohort study of urinary tract infection in children; GP, general 
practice; SAIL, Secure Anonymised Information Linkage; UTI, urinary tract infection; VUR, vesicoureteric reflux. 
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and Health Research (now Health and Care Research 
Wales) and sponsored by Cardiff University, and 
DUTY was funded by the National Institute for Health 
Research-Health Technology Assessment and spon-
sored by Bristol University.
SAIL Databank
The study will use the SAIL Databank to access routinely 
collected data outlined in table 1. SAIL is a repository 
for a broad range of routinely collected health and 
population data in Wales. SAIL will also act as a data 
safe haven for the clinical DUTY and EURICA data sets 
and data made available from NHS Digital and Indi-
vidual Health Boards. All data will be accessed via 
the SAIL Gateway following Information Governance 
Review Panel (IGRP) approval. SAIL Databank does 
not handle any identifiable data, therefore all data will 
be anonymised including data transferred from other 
information centres.19–21
NHS Digital
NHS Digital is the trading name of the Health and Social 
Care Information Centre. This study will access Hospital 
Episode Statistics (HES) data for participants of the DUTY 
and EURICA studies. All available inpatient and outpa-
tient records belonging to each study participant will 
be requested and approved by the Independent Group 
Advising on the Release of Data (IGARD) panel. The 
data requested include diagnosis, procedures and length 
of episode according to the codes of the 10th Revision of 
the International Statistical Classification of Diseases and 
Related Health Problems.
Public Health Wales
Public Health Wales will provide a data extract of urine 
microbiology culture results from all microbiology labo-
ratories in Wales (Datastore) for use with this project. 
This will be transferred to SAIL.
Individual Health Boards
Health boards in Wales will be approached to access 
anonymised radiology data for patients in data set 
1. A one off data extract of patient-level attendance 
data for patients born between 1 January 1994 and 
31 December 2012 who attended radiology between 
1994 and 2016 will be transferred to SAIL. Data 
extracted include examination performed, attendance 
data and the radiology report.
opportunity to opt out (data set 2)
Data set 1 uses routinely collected data that are fully 
anonymised so we do not require individual consent in 
order to access these data. Data set 2 involves partici-
pants from the DUTY and EURICA studies and there-
fore requires section 251 (s251) support of the 2006 
NHS Act approval from the Health Research Authority’s 
Confidentiality Advisory Group (CAG) to pass identi-
fiable participant data legally held by Cardiff Univer-
sity and Bristol University (as sponsors of the studies) 
to the data providers. This is using an opt-out/dissent 
model instead of obtaining further consent. In order 
to provide the opportunity for participants to dissent 
a letter has been developed to be sent to all parents 
of participants. Participants have the opportunity to 
contact the study team through an online web form, by 
email, text or telephone (details provided on website) 
and register their dissent. These participants who 
register their dissent will not be included in any of the 
data sets sent to the information centres and therefore 
will not appear in the data sets for analysis. A participant 
representative was consulted on the layout, wording 
and level of information contained in the participant 
opt-out letter and on the study website. A key consid-
eration was to communicate the data transfer process. 
The final letter was approved by both an NHS Research 
Ethics Committee and CAG committee as part of overall 
governance approval for the study.
data matching
For included data sets, data will be sent to NHS Digital 
and SAIL (via NHS Wales Informatics Service (NWIS), 
their trusted third party) for matching using a combina-
tion of NHS number, name, address and date of birth. 
Matching with NHS Digital data will be by exact matching 
on NHS number, date of birth and postcode. This has 
been conducted in other studies and achieved a high 
match rate (99.6%).22 NWIS match using NHS number, 
date of birth, sex and postcode. Data matching by NHS 
Digital will be separate from matching conducted by 
NWIS on behalf of SAIL. We would expect only a small 
number of participants matched to both English and 
Welsh NHS records; however, there is the possibility of 
this for those using services across the border to their 
current address.
the anonymised data set
For DUTY and EURICA participants, NHS Digital will 
retain the unique study ID assigned by the DUTY/
EURICA study, with the HES records after the matching 
process before it is sent to SAIL Databank. This ID will be 
retained for data transfer to ensure the data can be linked. 
The same applies to data sent to NWIS. Requested data 
will then be linked for each participant via SAIL using 
the unique study ID. The DUTY and EURICA clinical 
data sets will be transferred to SAIL following a process of 
deidentification. The data flow is shown in figure 1. The 
study ID will be replaced by an anonymised linking field 
(ALF) to enable all data sets to be linked at an individual 
level. The resulting data set will contain clinical variables 
(from DUTY, EURICA, SAIL and NHS Digital), deidenti-
fied demographic variables (eg, week of birth and lower 
super output area) and the ALF. The key between study 
ID and ALF will be retained and encrypted as a further 
safeguard. The ALF is further encrypted so that data sets 
and records cannot be linked across multiple projects a 
researcher has access to.
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study participants
A flow chart of participants in the study is shown in 
figure 2. Data set 1 (routine sampling) will be children 
born and resident in Wales for the first 5 years of life; 
who were less than 5 years old between 1999 and 2012. 
The main analysis will be on children born between 
1 January 2005 and 31 December 2009 to ensure that all 
of the first 5 years of life are covered by the dates when 
Datastore is available.
Data set 2 (systematic sampling from DUTY and 
EURICA) will be children who participated in the 
EURICA or DUTY studies, who were not withdrawn from 
the study and when provided with the opportunity to 
opt out, remained in the study. For research question 2 
Figure 1 The data flow for data set 2. ALF, anonymised linking field; DUTY, Diagnosis of Urinary Tract infection in Young 
children; EURICA, Welsh cohort study of Urinary Tract Infection in Children; NHS, National Health Service; NWIS, NHS Wales 
Informatics Service. 
Figure 2 Flow chart of study participants. DUTY, Diagnosis of Urinary Tract infection in Young children; GP, general 
practice; mcUTI, microbiologically confirmed urinary tract infection. 
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when comparing children with an mcUTI from data sets 
1 and 2, children in group 1 will be selected to match 
the DUTY and EURICA study eligibility criteria as closely 
as possible within the constraints of using routine data. 
Data sets 1 and 2 will be limited to children with an 
mcUTI associated with a GP consultation between March 
2008 and April 2012. For both data sets, the child’s 
mcUTI, associated with a GP consultation (defined as 
within 14 days prior to the sample), will be identified and 
defined as the index consultation. To limit the potential 
transfer of GP systematic sampling behaviour, children 
from group 1 with index consultations between 2008 and 
2012 at practices which participated in the EURICA study 
will be flagged as will children with index consultations 
between 2010 and 2012 at practices which participated in 
the DUTY study. Children will only be included once in 
each study period (ie, a child with a sample sent within 
the EURICA study period could also appear in the DUTY 
study period). In addition, we will apply the DUTY study 
exclusion criteria (where possible) to data set 1 to make 
them directly comparable to data set 2; therefore, chil-
dren will be excluded from the routine sampling cohort 
if any criterion met:
 ► Known neurogenic bladder (eg, spina bifida) or 
previous bladder surgery.
 ► Prescribed antibiotics in the 7 days prior to 
presentation.
 ► Taking immunosuppressant medication.
 ► Using urinary catheters.
Children with a history of UTI or vesicoureteric reflux 
(VUR) will not be excluded (and were not excluded from 
the DUTY or EURICA studies) and we will explore the 
impact of these risk factors on outcomes.
Exposure
UTI cases will be based on NHS laboratory results. For 
data set 1, this will be through microbiological culture 
data downloaded from Datastore. These data represent 
samples (from both community and hospital settings) 
which have been classified as positive or negative by 
NHS laboratories according to their standard operating 
procedures. We do not know how urine was sampled, 
and this is likely to vary between settings. In most cases, 
these are likely to be clean catch samples, but may include 
urine collection pads or bags (particularly in community 
samples) as recommended by NICE; or catheter or supra-
pubic aspiration in hospital samples.6 NHS laboratories 
take into consideration the nature of the urine sample in 
their reporting.23 For data set 2, we will use the results of 
microbiological culture from NHS laboratories collected 
during the DUTY and EURICA studies as some partici-
pants were from England (Datastore is Wales only). For 
data set 2, the presence of significant bacteriuria (pure or 
predominant growth of 100 000 cfu/mL of urine) will be 
used to define UTI.
For data set 1 we define the exposure period as <5 years 
and will be grouped as follows (figure 2):
Group 1: children with at least one mcUTI before their 
fifth birthday or before outcome of interest.
Group 2: children with at least one urine sample but 
no mcUTI before their fifth birthday or before out-
come of interest.
Group 3: children with no urine samples before their 
fifth birthday or before outcome of interest.
Exposure is a discrete time-varying covariate (0 (group 
2 or 3 no UTI or no sample respectively) until first expo-
sure of group 1 (mcUTI) thereafter) and each patient’s 
exposure status will be taken at the point of each outcome; 
otherwise the exposure status of the child at their fifth 
birthday will be taken.
For the main analyses, groups 2 and 3 will be consid-
ered together as having no mcUTI. Data set 2 will 
similarly be divided into three groups based on their 
index consultation when recruited into the DUTY and 
EURICA studies:
Group 4: children with an mcUTI.
Group 5: children who had a urine sample but no 
mcUTI.
Group 6: children who had no urine sample.
study variables
Table 2 shows a breakdown of the baseline data and 
possible covariates available for children and maternal 
characteristics from the data collection forms for 
EURICA and DUTY and Welsh Demographic Service, 
Welsh Electronic Cohort of Children and for a subset 
with GP records. The study outcomes are summarised 
in table 3.
Follow-up
Follow-up of all children in data sets 1 and 2 will 
continue until the first occurrence of any of: outcome, 
migration, death or end of follow-up; and for the 
subanalysis of GP data, if the patient leaves the GP 
practice linked to SAIL or the last data collection from 
the general practice. For the analysis of research ques-
tion 1, using only children whose whole first 5 years 
of life were covered by the dates that Datastore was 
available (excluding children whose first 5 years of 
life fall outside of Datastore availability) and limiting 
date of births to 1 January 2005 to 31 December 2009, 
will mean that the shortest follow-up period will 
be 7 years. Follow-up will be longer where data are 
available. For research question 2, we will examine 
outcomes at 30 days and at 1 year (short term), 1–5 
years (medium term) and >5 years (long term) after 
the index consultation.
Analysis
Sample size
Comparison of renal scarring in children routinely sampled for UTI 
with and without mcUTI
The sample size is based on the outcome of renal scar-
ring of children with and without mcUTI and taken as 
15%.8 Using an OR of 1.5 (a conservative effect size of 
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5% difference between groups), two-sided alpha 0.05, 
power=90% and given a ratio of 32:1 (children diag-
nosed with mcUTI:children with no UTI diagnosis) 
in the data set, we require 15 519 children (452 with 
mcUTI:15 067 without mcUTI) for analysis. Initial exam-
ination of the SAIL data set identified just under 13 000 
children less than 5 years old with UTI between 1999 and 
2012. As our sample size calculation requires 452 with 
Table 2 Child and maternal characteristics
Risk factor
Data set 1: routine 
sampling
Source
Data set 2: systematic sampling
Source
Age of child at first urine sample (group 1/2 only) or index 
consultation (data set 2)
Datastore EURICA and DUTY study data
Gender WECC EURICA and DUTY study data
Ethnicity WECC WECC and DUTY study data
Deprivation quintile at birth (taken from postcode at birth) WDS: Welsh index of 
multiple deprivation 
and Townsend score
Townsend score; EURICA and DUTY study 
data
Maternal age at birth (years) (category) WECC EURICA and DUTY Welsh participants only: 
WECC
Birth weight (g) (category) WECC EURICA and DUTY Welsh participants only: 
WECC
Gestational age at birth (weeks) (category) WECC EURICA and DUTY Welsh participants only: 
WECC
Ever breast fed WECC EURICA and DUTY study data
Uropathogen (Enterobacteriaceae or other) (mcUTI only) Datastore EURICA and DUTY study data
Antimicrobial resistance (mcUTI only) Datastore EURICA and DUTY study data
Congenital malformations (con mals)
Known to be associatedwith UTI/renal scarring PEDW
  1. Spina bifida/neurobladder NA: DUTY exclusion
  2. Renal/urinary system con mals including 
vesicoureteric reflux (VUR)
EURICA and DUTY study data
Possibly associatedwith UTI/renal scarring
  1. Down's syndrome PEDW; WECC EURICA and DUTY study data
  2. Cerebral palsy/other paralytic syndromes WECC EURICA and DUTY study data
Congenital malformations—major/minor WECC EURICA and DUTY Welsh participants only: 
WECC
Comorbidities
  1. Diabetes diagnosed under the age of 5 years PEDW EURICA and DUTY study data*
  2. Renal or urogenital surgery PEDW EURICA study data* DUTY exclusion
  3. Cancer PEDW EURICA and DUTY study data*
  4. Immunosuppressive disease PEDW EURICA and DUTY study data*
  5. Circumcision (aged <5 years) PEDW; GP EURICA and DUTY study data*
Factors for follow-up of study participants and research question 2
Symptoms and signs at index consultation – EURICA and DUTY study data
Management at index consultation GP EURICA and DUTY study data
Antenatal ultrasound urinary system abnormalities – EURICA and DUTY study data
Family history of UTI/urinary system problems – EURICA and DUTY study data
Recent antibiotics (7 days prior to index consultation) GP EURICA and DUTY* study data
*At time of index consultation.
DUTY, Diagnosis of Urinary Tract infection in Young children; EURICA, Welsh cohort study of urinary tract infection in children; GP, general 
practice; mcUTI, microbiologically confirmed UTI; NA, not applicable; PEDW, Patient Episode Database for Wales; UTI, urinary tract infection; 
WDS, Welsh Demographic Service; WECC, Welsh Electronic Cohort of Children. 
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UTI, we can be confident of adequate power for this study. 
However, the true proportion with renal scarring is likely 
to be less than that reported by Shaikh et al.8 Assuming 
a proportion of 8% with renal scarring in the mcUTI 
group, and an OR of 1.5 (2.5% difference), two-sided 
alpha=0.05, power=90% and a ratio of 32:1, a total of 
35 833 children (1044 with UTI:34 789 without UTI) are 
required for analysis, which is still achievable.
Comparison of systematically versus routinely sampled UTI
This sample size is constrained by the number of chil-
dren with a systematically sampled mcUTI by NHS lab 
(n=374). Using the lower estimate of renal scarring of 8% 
of routinely sampled UTIs, then a 5% difference (13% in 
the systematically sampled group) would give 89% power, 
with a two-sided alpha=0.05 and a ratio of 32:1 (routinely 
sampled UTIs 11 968:systematically sampled UTIs 374).
Both analyses use multivariable regression. Using 
Green’s24 formulae, assuming medium effect sizes 
(OR=1.5), a two-sided alpha=0.05 and power=80%, to test 
20 predictors in the multivariable regression model we 
require at least 159 children in total. This suggests that 
we will be adequately powered for both analyses (given 
these assumptions) to examine predictors of short and 
medium-term outcomes.
Statistical analysis
Data set 1: routine sampling of UTI
Research question 1: Comparison of medium (up to 
5 years) and longer term (≥5 years) outcomes in chil-
dren with mcUTI versus those without mcUTI in routine 
sampling.
Baseline variables will be described using appropriate 
descriptive summaries (n (%), mean (SD), median 
(IQR)) to summarise the population for the main anal-
yses by groups 1, 2 and 3 and any marked imbalance 
between the groups will be identified. The main compar-
ative analyses will be carried out at a child level since 
outcomes relate to an individual’s exposure to one or 
more UTIs and will test the null hypothesis that there 
are no differences in outcomes in the first 5 years and 
between the ages of 5 and 7 years. The primary analysis 
will consist of a comparison of rate of diagnosis of renal 
scarring (no renal scarring, renal scarring recorded <5 
years, renal scarring recorded 5–7 years) in children with 
mcUTI versus children with no mcUTI, using a multino-
mial regression model. Results will be reported as relative 
risk ratios alongside 95% CIs. A survival model will also be 
performed to model time to first renal scarring diagnosis 
taking into account competing risks (such as deaths and 
migration) and differences in time at risk and to allow us 
to look for this outcome using all available follow-up for 
each child (at least 7 years). We will estimate HRs with 
95% CIs for each exposure group.
We will construct a directed acyclic graph to inform our 
choice of variables to include in the analysis. Confounding 
variables such as those listed in table 2 and also mcUTI 
that could be considered to be on the causal pathway 
will be defined a priori. We will run multiple mediation 
analyses using renal scarring as the dependent variable, 
mcUTI as the mediation variable and confounders as 
the independent variables. First we will identify the inde-
pendent variables associated with renal scarring (using a 
univariable logistic (where scarring is rare) or log-linear 
regression model (where scarring is common)) and iden-
tify the mediation variables (mcUTI or not) that are asso-
ciated with the significant independent variables. These 
will all be included in the mediation model. For each 
of the significant independent variables, two regression 
models will be performed with and without the media-
tion variable. We will calculate the indirect effect (and the 
effect of the mediator) using the regression coefficients 
from both regression models.
Unadjusted and adjusted relative risk ratios will be esti-
mated, together with 95% CIs.
Several sensitivity analyses are proposed: the primary 
outcome will be expanded to include any renal pathology 
codes due to uncertainty around whether the renal scar-
ring codes are sufficiently sensitive to pick up all cases 
of renal scarring. In addition, we will explore using Read 
codes from GP notes to pick up additional renal scarring 
diagnoses. Two effect modifiers were identified as a basis 
for subgroup analyses for the primary outcome: gender 
of child and presence of any renal/urological congenital 
Table 3 Study outcomes
Data source
PEDW
(All Wales) GP
Datastore
(All Wales)
Primary outcome
Renal scarring ✓
Sensitivity analyses
  Any renal pathology 
codes
✓
  GP renal scarring codes ✓
Secondary outcomes
Hospital admissions ✓
Day cases ✓
Renal/urological surgery ✓
Hypertension ✓ ✓
Chronic kidney disease ✓ ✓
Renal failure ✓
UTIs ✓ ✓
Renal imaging ✓
GP consultations ✓
Antibiotics ✓
Dysfunctional voiding ✓
Microbiologically confirmed 
UTI (5–7 years follow-up)
✓
GP, general practice; PEDW, Patient Episode Database for Wales; 
UTI, urinary tract infection.
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anomalies. These preplanned analyses will be conducted 
by the inclusion of appropriate interaction terms in the 
models.
Secondary outcomes will be analysed using multino-
mial and time to event models (table 3). Poisson regres-
sion models will be used where the outcome is a count of 
event (eg, hospital admissions, GP consultations, antibi-
otics prescribed); results will be represented as incidence 
rate ratios alongside 95% CIs. Additionally, we will iden-
tify risk factors for renal scarring (as above, plus age at 
first mcUTI, bacterial type and resistance) in children 
presenting with a childhood mcUTI. In a subsample of 
children linked to GP data, the 14 days prior to the urine 
sample submission date will be examined to determine 
whether there was an associated GP consultation. We will 
then estimate the likely rate of GP-associated mcUTIs and 
the rate of mcUTIs submitted from another setting (such 
as out of hours, outpatients or as a result of a hospital 
admission). An identical analysis to the primary outcome 
will be taken to examine whether the risk of renal 
scarring differs between those with an mcUTI or not, 
between different settings and the interaction between 
the two. Where numbers allow, variation in outcome will 
be accounted for at the level of the general practice in a 
multilevel model. We will also describe the levels of urine 
sampling and incidence of mcUTI from general practice 
in the routine data.
Data set 2: systematic sampling of UTI
Detailed study data for DUTY and EURICA participants 
are available, including age, gender and deprivation, 
presenting features, GP diagnosis and acute management. 
Recruited children are already grouped into mcUTI 
or no mcUTI through the study microbiology data and 
outcomes will be compared according to these groups. 
Five-year inpatient hospital outcomes will be available for 
all EURICA and DUTY children (the last participant of 
DUTY study was recruited in April 2012). We will be able 
to describe serious short-term (30 days and less than 1 year 
after index consultation) and medium-term (1–5 years) 
outcomes, including hospital admission, renal imaging, 
renal scarring, VUR and renal failure outcomes for all 
children in this group using Patient Episode Database 
for Wales data in Wales and NHS Digital hospital data 
in England. We will be able to describe other outcomes, 
such as GP consultations, recurrent UTI, dysfunctional 
voiding, antibiotic prescriptions, hypertension, chronic 
kidney disease, using GP data on a subset. In Wales, Data-
store will also be used to look at the urine culture results 
and organism resistance profile for subsequent UTIs.
We will describe GP diagnosis from study data versus 
Read codes and acute management from the routine data 
in GP records for this cohort for later comparisons and 
also to explore the validity of using routinely collected 
data in these cases. We will also assess the validity of using 
Read codes to diagnose UTI against microbiological 
culture results and agreement will be measured using the 
kappa statistic.
Research question 2: Comparison of short and medi-
um-term outcomes in children with mcUTI: routine 
versus systematic sampling.
We will compare the outcomes in children with mcUTI 
identified through routine versus systematic sampling. 
Children’s characteristics, presentation factors, acute 
management and microbiology results will be described 
for the groups using appropriate summary statistics. We 
will compare urine sampling and UTI diagnosis in consul-
tations between routine and systematic sampling. In addi-
tion, we will describe blood pressure and creatinine levels 
for each group if recorded and explore whether compar-
isons can be made.
Previously mentioned short and medium-term outcomes 
will be described by the two groups of routine versus selec-
tive sampling. Predictors of outcome will be examined as 
before using a multilevel multinomial regression model 
(no event, 30 days, event 30 days to 1 year, event 1–5 years) 
and again where numbers allowed, variation in outcome 
will be accounted for at the level of the general practice. 
Associations between covariates previously described and 
outcome will first be examined. Unadjusted and adjusted 
relative risk ratios will be estimated, together with 95% 
CIs. We will compare blood pressure and creatinine levels 
(where available) across the groups; we expect these data 
to be limited so will be exploratory.
A detailed statistical analysis plan will be written prior 
to database lock. The reporting and presentation of 
results will be in accordance with the25–27 statements to 
ensure the comprehensive reporting of our observational 
non-randomised evaluation of a public health interven-
tion. SPSS (Version 25) and Stata (StataCorp, 2017) will 
be used for all analyses.28
Patient and public involvement
We have a parent representative (Sarah Jones) who has 
contributed to all stages of this study. She helped organise 
a parent group to discuss information provided to DUTY 
and EURICA study participants explaining the study 
and opt-out mechanism. She also provided input on the 
study website and on the procedure in place to manage 
contacts made by the participants. During the drafting of 
the statistical analysis plan we discussed the planned anal-
yses with her, and she identified which of the analyses that 
she felt would be of most interest to parents of children 
with suspected UTI. Results will be disseminated via the 
study website and other channels with the input from our 
parent representative.
Ethics and dissemination
The governance surrounding data set 1 differs from 
data set 2. Data set 1 is an anonymised data set made avail-
able from SAIL Databank with only approval required 
from the IGRP whereas data set 2 involves the transfer of 
identifiable data to data providers which requires ethical 
approval, s251 support, IGRP and IGARD approval. In 
order to obtain an unbiased sample from the DUTY and 
EURICA cohorts, an opt-out consent model is being used; 
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this was supported by both the ethics panel and the CAG 
panel as justification for this model of consent.
The LUCI study will report the risk of renal scarring for 
children with and without childhood mcUTI across the 
whole of Wales. The linking of routinely collected data sets 
will give us a large cohort including demographic, hospital 
inpatient and outpatient, GP and microbiology data, 
allowing us to define mcUTI cases and describe outcomes 
for all children from both primary and secondary care. 
Clarifying the link between UTI, renal scarring and 
long-term complications will inform the management of 
acutely ill children in primary care, where the need for 
urine sampling is unclear. Determining the clinical impli-
cations of ‘missed’ cases of UTI through our comparison 
of children with mcUTI identified through routine and 
systematic urine sampling will also help determine the 
most appropriate urine sampling strategy. This study 
maximises the benefits of the previously funded DUTY 
and EURICA cohorts, representing over 8000 acutely ill 
children recruited from UK primary care. Significant 
resources were invested by funders, patients and staff to 
develop these cohorts. Routine data linkage will allow us 
to determine longer term outcomes for these children 
and to determine risks of adverse outcomes. It will also 
pave the way for even longer term follow-up of cohorts 
of children with UTI (diagnosed both systematically and 
routinely) which has been identified as a high research 
priority by NICE.
A lay summary of the results and links to publications 
will be made available on the University project website. 
The academic outputs for this study include (1) this 
protocol paper, (2) main results from research question 
1, and (3) main results from research question 2. The 
findings from this study will be of interest to clinicians 
and policymakers and may influence the management of 
acutely ill children and childhood UTI.
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